Peripheral Arterial Occlusive Disease

5
Pipeline Programs
3
Companies
3
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
ALPROSTADILApproved
alprostadil
Unknown Company
Prostaglandin Analog [EPC]injection1999
U
EDEXApproved
alprostadil
Unknown Company
Prostaglandin Analog [EPC]injection1997

Competitive Landscape

2 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
1 program
1
AlprostadilPhase 41 trial
Active Trials
NCT00596752Completed840Est. Jul 2013
Sanofi
SanofiPARIS, France
2 programs
2
XRP0038Phase 11 trial
XRP0038Phase 11 trial
Active Trials
NCT01157143Completed6Est. Oct 2003
NCT01157156Completed51Est. Sep 2001

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UCB PharmaAlprostadil
SanofiXRP0038
SanofiXRP0038

Clinical Trials (3)

Total enrollment: 897 patients across 3 trials

NCT00596752UCB PharmaAlprostadil

Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV

Start: Mar 2004Est. completion: Jul 2013840 patients
Phase 4Completed
NCT01157143SanofiXRP0038

Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation

Start: Jan 2002Est. completion: Oct 20036 patients
Phase 1Completed
NCT01157156SanofiXRP0038

Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

Start: Jun 1999Est. completion: Sep 200151 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space